Uni Pharma Co Ltd

Uni Pharma's capital structure is characterized by a low debt-to-equity ratio of 0.05, indicating a conservative leverage profile. The company holds a current ratio of 4.86, suggesting strong short-term liquidity. However, its operating cash flow is negative at -36.67 million TWD, and free cash flow is also negative at -35.42 million TWD, signaling cash flow constraints. Profitability metrics are weak, with a return on equity of -17.64% and a return on assets of -14.74%, both significantly below the industry median for Advanced Medical Equipment & Technology. The company reported a net loss of 40.54 million TWD and an operating loss of 44.13 million TWD, reflecting operational inefficiencies and cost pressures. The company's revenue is concentrated in its core wholesale operations, with no disclosed geographic diversification. While the input data does not provide segment-specific revenue breakdowns, the lack of geographic exposure details suggests potential concentration risk in its domestic market. Uni Pharma's growth trajectory is uncertain, with no disclosed revenue growth rates or outlooks. The company's operating income and net income have turned negative, and its free cash flow is negative, indicating a lack of momentum in revenue expansion or cost control. Risk factors include liquidity constraints, as evidenced by negative operating and free cash flows, and the absence of positive returns on equity or assets. The company has no immediate filing-based liquidity or dilution flags, and its dilution risk is assessed as low. However, the negative cash flows and weak profitability metrics suggest potential operational and financial risks. Recent events and filings do not indicate any material changes in the company's operations or financial position. The absence of recent capital raises or significant debt issuance suggests a stable but stagnant capital structure.